Post job

Explore jobs

Find specific jobs

Explore careers

Explore professions

Best companies

Explore companies

Kura Oncology CEO and leadership

Zippia score 3.9
Job openings (13)
OverviewJobsRevenue

Reviews

History

CEO & Executives

Kura Oncology CEO and executives

Executive Summary. Based on our data team's research, Troy E. Wilson Ph.d is the Kura Oncology's CEO. Kura Oncology has 121 employees, of which 27 are in a leadership position.
Here are further demographic highlights of the leadership team:
  • The Kura Oncology executive team is 44% female and 56% male.
  • 61% of the management team is White.
  • 11% of Kura Oncology management is Hispanic or Latino.
  • 10% of the management team is Black or African American.
Work at Kura Oncology?
Share your experience

Rate Kura Oncology's leaders' effectiveness in guiding the company.

Zippia waving zebra
Name & TitleBio
Troy E. Wilson Ph.d

President and Chief Executive Officer

Troy E. Wilson Ph.d's LinkedIn

Troy Wilson is a highly-successful, serial entrepreneur. His passion is to build exceptional companies that create significant value for employees, investors and most importantly, patients. In addition to his role as President and CEO of Avidity NanoMedicines, Troy Wilson is President and CEO of Wellspring Biosciences as well as its affiliated company, Araxes Pharma. He also serves as a director of Puma Biotechnology, a biopharmaceutical company dedicated to the acquisition and development of novel therapeutics for the treatment of cancer. Troy Wilson previously served as President and CEO of Intellikine, a company which he co-founded and which was acquired by Takeda Pharmaceuticals in January 2012 for up to $310 million, and prior to Intellikine he was involved with the formation, launch and growth of several other companies. Troy Wilson received his Ph.D. degree in bioorganic chemistry from the University of California, Berkeley and his law degree from New York University.

Antonio Gualberto

Founder

Pingda Ren

Founder

Yi Liu

Founder

Diane L. Parks

Board Member

Faheem Hasnain

Board Member

Kathleen Ford

Chief Operating Officer

Kirsten Flowers

Chief Commercial Officer

Mary T. Szela

Board Member

Steven H. Stein

Board Member

Do you work at Kura Oncology?

Does leadership effectively guide Kura Oncology toward its goals?

Kura Oncology jobs

Kura Oncology founders

Name & TitleBio
Troy E. Wilson Ph.d

President and Chief Executive Officer

Troy E. Wilson Ph.d's LinkedIn

Troy Wilson is a highly-successful, serial entrepreneur. His passion is to build exceptional companies that create significant value for employees, investors and most importantly, patients. In addition to his role as President and CEO of Avidity NanoMedicines, Troy Wilson is President and CEO of Wellspring Biosciences as well as its affiliated company, Araxes Pharma. He also serves as a director of Puma Biotechnology, a biopharmaceutical company dedicated to the acquisition and development of novel therapeutics for the treatment of cancer. Troy Wilson previously served as President and CEO of Intellikine, a company which he co-founded and which was acquired by Takeda Pharmaceuticals in January 2012 for up to $310 million, and prior to Intellikine he was involved with the formation, launch and growth of several other companies. Troy Wilson received his Ph.D. degree in bioorganic chemistry from the University of California, Berkeley and his law degree from New York University.

Antonio Gualberto

Founder

Pingda Ren

Founder

Yi Liu

Founder

Kura Oncology board members

Name & TitleBio
Troy E. Wilson Ph.d

President and Chief Executive Officer

Troy E. Wilson Ph.d's LinkedIn

Troy Wilson is a highly-successful, serial entrepreneur. His passion is to build exceptional companies that create significant value for employees, investors and most importantly, patients. In addition to his role as President and CEO of Avidity NanoMedicines, Troy Wilson is President and CEO of Wellspring Biosciences as well as its affiliated company, Araxes Pharma. He also serves as a director of Puma Biotechnology, a biopharmaceutical company dedicated to the acquisition and development of novel therapeutics for the treatment of cancer. Troy Wilson previously served as President and CEO of Intellikine, a company which he co-founded and which was acquired by Takeda Pharmaceuticals in January 2012 for up to $310 million, and prior to Intellikine he was involved with the formation, launch and growth of several other companies. Troy Wilson received his Ph.D. degree in bioorganic chemistry from the University of California, Berkeley and his law degree from New York University.

Diane L. Parks

Board Member

Faheem Hasnain

Board Member

Mary T. Szela

Board Member

Steven H. Stein

Board Member

Thomas R. Malley

Board Member

Carol Anne Schafer

Board Member

Helen Collins

Board Member

Kura Oncology executives FAQs

Most in demand jobs

Updated November 18, 2022

Zippia gives an in-depth look into the details of Kura Oncology, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Kura Oncology. The employee data is based on information from people who have self-reported their past or current employments at Kura Oncology. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Kura Oncology. The data presented on this page does not represent the view of Kura Oncology and its employees or that of Zippia.

Kura Oncology may also be known as or be related to KURA ONCOLOGY INC., Kura Oncology, Kura Oncology Inc and Kura Oncology, Inc.